Cassava sciences topline phase 3 data did not meet co-primary endpoints

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate alzheimer's disease in the rethink-alz phase 3 study
sava Ratings Summary
sava Quant Ranking